Published in Vaccine Weekly, February 21st, 2001
"Human leukocyte antigen (HLA) polymorphism can complicate the design and development of vaccines, especially those that contain a selected number of epitopes and are directed at pathogens prevalent worldwide," wrotes D.V. Dawson and colleagues, Case Western Reserve University, Cleveland, Ohio. "Because of HLA class I restricted antigen recognition and ethnic variation in HLA distribution, such vaccines may not be uniformly effective across populations." Dawson et al. published the results of their study in the journal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.